Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors

被引:132
|
作者
Xu, KL
Ma, H
McCown, TJ
Verma, IM
Kafri, T
机构
[1] Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA
[4] Salk Inst, Genet Lab, La Jolla, CA 92307 USA
关键词
lentiviral vectors; transduction; expression; neurons;
D O I
10.1006/mthe.2000.0238
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
To facilitate the generation of SIN lentivirus vector-producer cell lines, we have developed a novel conditional SIN (cSIN) lentivirus vector, which retains its SIN properties in normal target cells yet can be produced at high titers from tetracycline-regulated packaging cell lines. The design of the cSIN vector is based on replacing the vector U3 transcription regulatory elements with the Tet-responsive element, which allows vector production exclusively in cells expressing the synthetic Tet-regulated transactivator (tTA). In contrast minimal vector production (similar to 200 IU/ml) is obtained in target cells that do not express the tTA, even in the presence of all HIV-1 proteins. Following transduction of the Tet-regulated SODk1 lentivirus vector-packaging cell line with the cSIN vector, high titers of cSIN recombinant vector (>10(6) IU/ml) could be generated, which efficiently transduced terminally differentiated neurons in normal rat brain.
引用
收藏
页码:97 / 104
页数:8
相关论文
共 50 条
  • [21] RD3-MolPack packaging cells for stable production of Tat-independent self-inactivating lentiviral vectors
    Stornaiuolo, A.
    Bossi, S.
    Corna, S.
    Zucchelli, E.
    Bordignon, C.
    Rizzardi, G. P.
    Bovolenta, C.
    HUMAN GENE THERAPY, 2013, 24 (12) : A95 - A95
  • [22] Self-Inactivating Lentiviral Vectors for Correction of Rag1 Severe Combined Immunodeficiency
    Pike-Overzet, K.
    Rodijk, M.
    Ng, Y. Y.
    Baert, M. R. M.
    Lagresle-Peyrou, C.
    Schambach, A.
    Zhang, F.
    Hoeben, R. C.
    Hacein-Bey-Abina, S.
    Lankester, A. C.
    Bredius, R. G. M.
    Driessen, G. J. A.
    Thrasher, A. J.
    Baum, C.
    Cavazzana-Calvo, M.
    van Dongen, J. J. M.
    Staal, F. J. T.
    HUMAN GENE THERAPY, 2012, 23 (10) : A42 - A42
  • [23] Self-Inactivating Lentiviral Vectors for Correction of Rag1 Severe Combined Immunodeficiency
    Pike-Overzet, Karin
    Wiekmeijer, Anna-Sophia
    Baert, Miranda R. M.
    Lagresle-Peyrou, Chantal
    Schambach, Axel
    Zhang, Fang
    Hoeben, Rob C.
    Hacein-Bey-Abina, Salima
    Lankester, Arjen C.
    Bredius, Robbert G. M.
    Driessen, Gertjan J. A.
    Thrasher, Adrian J.
    Baum, Christopher
    Cavazzana-Calvo, Marina
    van Dongen, Jacques J. M.
    Staal, Frank J. T.
    MOLECULAR THERAPY, 2013, 21 : S120 - S121
  • [24] Self-inactivating lentiviral vectors with U3 and U5 modifications
    Iwakuma, T
    Cui, Y
    Chang, LJ
    VIROLOGY, 1999, 261 (01) : 120 - 132
  • [25] SELF-INACTIVATING LENTIVIRAL VECTORS FOR CORRECTION OF RAG1 SEVERE COMBINED IMMUNODEFICIENCY
    Pike-Overzet, Karin
    Rodijk, Mark
    Ng, Yuk Yin
    Baert, Miranda
    Lagresle-Peyrou, Chantal
    Schambach, Axel
    Zhang, Fang
    Hoeben, Rob
    Hacein-Bey-Abina, Salima
    Lankester, Arjan
    Bredius, Robbert
    Driessen, Gertjan
    Thrasher, Adrian
    Baum, Christopher
    Cavazzana-Calvo, Marina
    van Dongen, Jacques
    Staal, Frank
    EXPERIMENTAL HEMATOLOGY, 2012, 40 (08) : S46 - S47
  • [26] Development of a stable, inducible (N-1) cell line for the efficient and high titer production of lentiviral vectors
    George, H.
    George, H.
    Pegg, L.
    Spencer, A.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A103 - A103
  • [27] Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media
    K Ghani
    S Cottin
    A Kamen
    M Caruso
    Gene Therapy, 2007, 14 : 1705 - 1711
  • [28] Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media
    Ghani, K.
    Cottin, S.
    Kamen, A.
    Caruso, M.
    GENE THERAPY, 2007, 14 (24) : 1705 - 1711
  • [29] Systemic injection in a tumor prone mouse unravels the residual genotoxicity of self-inactivating lentiviral vectors
    Cesana, D.
    Ranzani, M.
    Bartholomae, C.
    Volpin, M.
    Benedicenti, F.
    VonKalle, C.
    Schmidt, M.
    Naldini, L.
    Montini, E.
    HUMAN GENE THERAPY, 2010, 21 (10) : 1484 - 1484
  • [30] Cell- and vector-engineering approaches for manufacturing high-titer GaLV pseudotyped lentiviral vectors from stable and constitutive producer cell lines
    Rodrigues, A. F.
    Nogueira, R.
    Vaz, T. A.
    Carrondo, M. J. T.
    Coroadinha, A. S.
    HUMAN GENE THERAPY, 2019, 30 (11) : A4 - A5